{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:08:10Z","timestamp":1787846890578,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib\/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib\/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and\/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and\/or del17p abnormalities. Minimal residual disease (MRD; 10<jats:sup>\u22125<\/jats:sup> sensitivity threshold) was assessed via the clonoSEQ\u00ae assay V2.0. Of the 498 patients randomized, 40 (16%) in the D-Vd group and 35 (14%) in the Vd group were categorized as high risk.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>After a median follow-up of 40.0\u2009months, D-Vd prolonged median PFS versus Vd in patients with standard (16.6 vs 6.6\u2009months; HR, 0.26; 95% CI, 0.19-0.37; <jats:italic>P<\/jats:italic> &lt; 0.0001) and high (12.6 vs 6.2\u2009months; HR, 0.41; 95% CI, 0.21\u20130.83; <jats:italic>P<\/jats:italic> = 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall population of CASTOR.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>ClinicalTrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02136134\">NCT02136134<\/jats:ext-link>. Registered 12 May 2014<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13045-020-00948-5","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T11:02:57Z","timestamp":1597921377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk"],"prefix":"10.1186","volume":"13","author":[{"given":"Katja","family":"Weisel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer M.","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Lauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Munder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolney","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher A.","family":"Chanan-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Capra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ovilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tineke","family":"Casneuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himal","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Ukropec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"issue":"3","key":"948_CR1","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840\u20138.","journal-title":"J Immunol"},{"issue":"21","key":"948_CR2","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","volume":"124","author":"J Lammerts van Bueren","year":"2014","unstructured":"Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124(21):3474.","journal-title":"Blood"},{"issue":"2","key":"948_CR3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk MB, Verploegen S, Bogels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311\u201321.","journal-title":"MAbs."},{"issue":"3","key":"948_CR4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"MB Overdijk","year":"2016","unstructured":"Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking. J Immunol. 2016;197(3):807\u201313.","journal-title":"J Immunol"},{"issue":"3","key":"948_CR5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384\u201394.","journal-title":"Blood."},{"key":"948_CR6","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V128.22.4531.4531","volume":"128","author":"C Chiu","year":"2016","unstructured":"Chiu C, Casneuf T, Axel A, Lysaght A, Bald J, Khokhar NZ, et al. Daratumumab in combination with lenalidomide plus dexamethasone induces clonality increase and T-cell expansion: results from a phase 3 randomized study (POLLUX). Blood. 2016;128:4531.","journal-title":"Blood."},{"issue":"3","key":"948_CR7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","volume":"95","author":"HC Adams 3rd","year":"2019","unstructured":"Adams HC 3rd, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, et al. High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry A. 2019;95(3):279\u201389.","journal-title":"Cytometry A"},{"key":"948_CR8","unstructured":"DARZALEX\u2122 (daratumumab) injection, for intravenous use [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2018."},{"issue":"8","key":"948_CR9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754\u201366.","journal-title":"N Engl J Med"},{"key":"948_CR10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood.V128.22.246.246","volume":"128","author":"H Avet-Loiseau","year":"2016","unstructured":"Avet-Loiseau H, Casneuf T, Chiu C, Laubach JP, Lee JJ, Moreau P, et al. Evaluation of minimal residual disease (MRD) in relapsed\/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone. Blood. 2016;128:246.","journal-title":"Blood."},{"key":"948_CR11","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Sonneveld P, Hungria VTM, Nooka AK, Estell J, Barreto WG, et al. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients: two-year update of CASTOR. Poster presented at: 60th Annual Meeting of the American Society of Hematology; December 1-4, 2018; San Diego, CA.Abstract 3270.","DOI":"10.1182\/blood-2018-99-112554"},{"issue":"24","key":"948_CR12","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955\u201362.","journal-title":"Blood."},{"key":"948_CR13","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","volume":"5","author":"AM Rajan","year":"2015","unstructured":"Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015;5:e365.","journal-title":"Blood Cancer J"},{"issue":"12","key":"948_CR14","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","volume":"23","author":"R Fonseca","year":"2009","unstructured":"Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210\u201321.","journal-title":"Leukemia."},{"issue":"12","key":"948_CR15","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","volume":"103","author":"A Spencer","year":"2018","unstructured":"Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103(12):2079\u201387.","journal-title":"Haematologica."},{"issue":"9","key":"948_CR16","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","journal-title":"Leukemia."},{"issue":"18","key":"948_CR17","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691\u20135.","journal-title":"Blood."},{"key":"948_CR18","doi-asserted-by":"crossref","unstructured":"Mateos MV, Estell J, Barreto W, Corradini P, Min CK, Medvedova E, et al., editors. Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of CASTOR. Presented at the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH); December 3-6, 2016; San Diego, CA Abstract 1150; 2016.","DOI":"10.1182\/blood.V128.22.1150.1150"},{"issue":"6","key":"948_CR19","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/leu.2016.390","volume":"31","author":"WJ Chng","year":"2016","unstructured":"Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2016;31(6):1368\u201374.","journal-title":"Leukemia."},{"issue":"9","key":"948_CR20","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","volume":"128","author":"H Avet-Loiseau","year":"2016","unstructured":"Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016;128(9):1174\u201380.","journal-title":"Blood."},{"issue":"11","key":"948_CR21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195\u2013206.","journal-title":"Lancet Oncol"},{"key":"948_CR22","doi-asserted-by":"crossref","unstructured":"Kaufman JL, Dimopoulos MA, Leiba M, Morton J, Ho PJ, Kim K, et al. Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): updated subgroup analysis of POLLUX based on cytogenetic risk. J Clin Oncol. 2019;37(suppl): Abstract 8038.","DOI":"10.1200\/JCO.2019.37.15_suppl.8038"},{"issue":"10","key":"948_CR23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2014.117077","volume":"100","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015;100(10):1327\u201333.","journal-title":"Haematologica."},{"issue":"8","key":"948_CR24","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","volume":"109","author":"H Avet-Loiseau","year":"2007","unstructured":"Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489\u201395.","journal-title":"Blood."},{"key":"948_CR25","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome experience. J Clin Oncol. 2013;31(22):2806\u20139.","DOI":"10.1200\/JCO.2012.46.2598"},{"issue":"2","key":"948_CR26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269\u201377.","journal-title":"Leukemia."},{"issue":"1","key":"948_CR27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","volume":"204","author":"JR Sawyer","year":"2011","unstructured":"Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Gene Ther. 2011;204(1):3\u201312.","journal-title":"Cancer Gene Ther"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00948-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00948-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00948-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T23:44:05Z","timestamp":1629416645000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00948-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00948-5","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"8 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by an independent ethics committee or institutional review board at each study center and was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KW received honoraria from GlaxoSmithKline, Sanofi, Adaptive, Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda; served in a consulting or advisory role for GlaxoSmithKline, Amgen, Adaptive, Bristol-Myers Squibb, Celgene, Janssen, Takeda, Sanofi, and Juno; and received institutional research funding from Amgen, Celgene, Sanofi, and Janssen. AS received honoraria from Celgene, Janssen, Amgen, AbbVie, Servier, and Takeda; served in a consulting or advisory role for Celgene, Janssen, Servier, and AbbVie; and served on a speakers bureau for and received institutional funding from Janssen, Takeda, and Celgene. SL holds stock and patents, royalties, or other intellectual property from Caelum Biosciences; served in a consulting or advisory role for Caelum Biosciences, Takeda, Janssen, Celgene, Bristol-Myers Squibb, AbbVie, and Bayer; received research funding from Sanofi; declared another relationship with Clinical Care Options; and served on data safety monitoring boards for Sorrento and Bayer. TMM holds stock in AbbVie; received honoraria and research funding from Celgene; and served in a consulting or advisory role for Janssen, Takeda, and Adaptive. M-DL is a consultant for and receives honoraria and travel support from AbbVie, Celgene, Amgen, and Janssen. AB received honoraria from Amgen; served in a consulting or advisory role for Takeda; and had travel, accommodations, or other expenses paid or reimbursed by Celgene, Janssen, and Amgen. VH served in a consulting or advisory role and on a speakers bureau for AbbVie, Amgen, Celgene, Janssen, Takeda, and Bristol-Myers Squibb. MCavo received honoraria from Celgene, Janssen, Amgen, Bristol-Myers Squibb, AbbVie, and Takeda; served in a consulting or advisory role for Janssen, Celgene, Amgen, and AbbVie; and served on a speakers bureau for and had travel, accommodations, or other expenses paid or reimbursed by Janssen and Celgene. AN received honoraria from and served in a consulting or advisory role for Janssen, GlaxoSmithKline, Celgene, Amgen, Takeda, Spectrum, Bristol-Myers Squibb, Karyopharm, Oncopeptides, and Adaptive and received research funding from Janssen, GlaxoSmithKline, Celgene, Amgen, Takeda, Karyopharm, and Bristol-Myers Squibb. HQ served in a consulting or advisory role for Celgene, Amgen, Karyopharm, and GlaxoSmithKline and received research funding from Celgene and Amgen. MM received honoraria from Janssen, Bristol-Myers Squibb, Celgene, and Amgen; served in a consulting or advisory role for Janssen, Bristol-Myers Squibb, Takeda, Celgene, Amgen, and Heidelberg Pharma; received research funding from Incyte and Bristol-Myers Squibb; and had travel, accommodations, or other expenses paid or reimbursed by Janssen, Bristol-Myers Squibb, Takeda, Celgene, and Amgen. CL received honoraria from and consulted for Amgen, Janssen-Cilag, Takeda, and Celgene. PC received honoraria from Daiichi Sankyo, Kite, KiowaKirin, Celgene, Janssen, Novartis, Roche, Takeda, Sanofi, Amgen, Gilead, and AbbVie and had travel, accommodations, or other expenses paid or reimbursed by Novartis, Janssen, Celgene, Bristol-Myers Squibb, Takeda, Gilead, Amgen, and AbbVie. AAC-K received research funding from the Mayo Clinic. NH served on the board of directors or advisory committees for Janssen. MCapra received honoraria from AbbVie, GlaxoSmithKline, Bristol-Myers Squibb, Adaptive, Takeda, Janssen, and Celgene. MB served in a consulting or advisory role and on a speakers bureau for Amgen, Janssen, and Takeda. RO consulted for Janssen. PS received honoraria from and research funding from Amgen, Celgene, Janssen, SkylineDx, and Takeda. TC is an employee of Janssen and holds stock options from Johnson & Johnson. ND, HA, JU, and RK are employees of Janssen. M-VM received honoraria from and served in a consulting or advisory role for Janssen, Celgene, Amgen, Takeda, GlaxoSmithKline, AbbVie, Seattle Genetics, and Adaptive. HA-L, IS, TM, BL, J-JL, WB, C-KM, J-CJ, and H-JS have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}